“It’s a time for great hope with breast cancer, given the number of agents being evaluated now.” –Sara A. Hurvitz, MD
ONCOLOGY Staff
Advertisement
Articles by ONCOLOGY Staff
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Companion Diagnostic for Niraparib in Advanced Ovarian Cancer
2
NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium
3
Atirmociclib/Fulvestrant Improves PFS in HR+/HER2– Breast Cancer
4
Emerging Strategies in Prostate Cancer: Molecular Glues and T-Cell Engagers
5